TEAM II: a randomised, multicentre, prospective, phase III trial investigating neoadjuvant hormonal therapy with exemestane for three versus six months (TEAM IIa) and/or the efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer (TEAM IIb)

Trial Profile

TEAM II: a randomised, multicentre, prospective, phase III trial investigating neoadjuvant hormonal therapy with exemestane for three versus six months (TEAM IIa) and/or the efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer (TEAM IIb)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2015

At a glance

  • Drugs Exemestane (Primary) ; Ibandronic acid (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TEAM-II; TEAM-IIa; TEAM-IIb
  • Most Recent Events

    • 01 Oct 2013 Preliminary results presented at the 2013 European Cancer Congress.
    • 05 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top